A long-term comparison of proquazone and naproxen in the treatment of osteoarthritis of the hip.

Abstract

The efficacy and tolerance of 900 mg/day proquazone were compared with those of 500 mg/day naproxen in a three-month trial with 40 patients suffering from osteoarthritis of the hip. Proquazone was found to be more effective than naproxen in providing relief of symptoms and improving the patient's condition. The side effects of proquazone were exclusively gastrointestinal but occurred more frequently than with naproxen. With one exception, none of the symptoms were serious enough to require suspension of therapy. These results suggest that the action of proquazone provides a good balance between clinical efficacy and tolerance.

• Authors: J T Vainio, P V Lepistö
• Journal: Scandinavian journal of rheumatology. Supplement (Scand J Rheumatol Suppl) Issue 21 Pg. 25-7 ( 1978) ISSN: 0301-3847 [Print] Norway
• PMID: 356238 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)

Chemical References

• Anti-Inflammatory Agents
• Quinazolines
• Naproxen

Topics

• Adult
• Aged
• Anti-Inflammatory Agents (adverse effects, therapeutic use)
• Clinical Trials as Topic
• Drug Evaluation
• Female
• Hip Joint
• Humans
• Male
• Middle Aged
• Naproxen (adverse effects, therapeutic use)
• Osteoarthritis (drug therapy)
• Quinazolines (adverse effects, therapeutic use)
• Time Factors